Apogee Therapeutics Reports Financial Results and Clinical Trial Updates in Annual Filing

Apogee Therapeutics, Inc., a clinical-stage biotechnology company, released its financial results and provided updates on its clinical trial programs in its recent 10-K filing. The company, which focuses on developing novel biologics for inflammatory and immunology (I&I) indications, reported a net loss of $255.8 million for the year ended December 31, 2025, compared to a net loss of $182.1 million for the previous year. This increase in net loss is primarily attributed to escalating research and development expenses as the company advances its clinical programs. As of December 31, 2025, Apogee held $131.5 million in cash and cash equivalents, $598.6 million in marketable securities, and $172.7 million in long-term marketable securities.

The company's research and development expenses for 2025 totaled $214.7 million, a significant increase from the $167.9 million reported in 2024. This rise is largely due to the progression of zumilokibart (APG777), its lead product candidate, through clinical trials, as well as increases in personnel costs and equity-based compensation. General and administrative expenses also saw an increase, reaching $70.9 million in 2025 compared to $49.0 million in 2024, driven by higher headcount and associated costs related to operating as a public company. Interest income decreased slightly from $34.7 million in 2024 to $30.0 million in 2025, reflecting changes in investment yields and balances.

Operationally, Apogee has been actively advancing its pipeline. The company highlighted positive interim data from a Phase 1b trial of APG808 in patients with mild-to-moderate asthma, and announced positive 16-week data from the Part A portion of the APEX Phase 2 clinical trial evaluating zumilokibart in patients with moderate-to-severe atopic dermatitis (AD). Furthermore, Apogee commenced dosing in the Phase 1b trial of APG279 against DUPIXENT in patients with moderate-to-severe AD, and completed Part B enrollment of the APEX Phase 2 trial ahead of schedule. The company also entered into a separate PSA with Samsung that would provide for the commercial manufacture of zumilokibart drug substance should the program eventually receive regulatory approval. As of December 31, 2025, Apogee had 261 full-time employees, with 191 dedicated to research and development.

Looking ahead, Apogee anticipates reporting Part A maintenance data from the APEX Phase 2 clinical trial in March 2026 and 16-week topline induction data from Part B in the second quarter of 2026. Subject to positive results and regulatory alignment with the FDA, the company plans to initiate a Phase 3 trial in AD in the second half of 2026, potentially leading to a launch of zumilokibart for the treatment of AD in 2029. Based on its clinical data, Apogee expects to further evaluate additional opportunities to develop zumilokibart for other I&I indications, including alopecia areata, chronic rhinosinusitis with nasal polyps (“CRSwNP”), chronic spontaneous urticaria, and prurigo nodularis. The company estimates that its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements into the second half of 2028.

About Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company developing novel biologic therapies for inflammatory and immunology (I&I) diseases such as atopic dermatitis, asthma, eosinophilic esophagitis, and COPD. Its pipeline features engineered monoclonal antibodies with extended half-life modifications targeting IL-13, OX40L, TSLP, and IL-4Rα. Apogee aims to improve efficacy and reduce dosing frequency, addressing unmet needs through optimized antibody design and combination therapies.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.